US Clot Management Devices Market - 2016
|出版商||iData Research Inc.||商品編碼||347788|
|出版日期||內容資訊||英文 53 Pages
所謂肺栓塞症，是血栓從人體其他部位朝肺的內部移動、集積，阻塞肺動脈的疾病，美國每年有60萬人以上發病。抗凝固療法成為治療方法的第一選項，不過，也有第二選項，用下腔靜脈濾器 (IVCF) 和血栓去除裝置，去除肺動脈血栓的方法。這2個治療方法中，血栓去除裝置，尤其是動靜脈 (AV) 進入設備成為最成熟的治療方法。
本報告提供美國的血栓管理設備 (血栓去除裝置、下腔靜脈濾器) 的市場相關分析、各產品市場結構和最新趨勢、市場整體及產品單位的市場趨勢預測、主要的推動及阻礙市場要素、市場競爭情形等調查評估。
The total thrombectomy device market comprises thrombectomy devices used in arteriovenous (AV) access thrombectomy procedures, arterial thrombectomy procedures and venous thrombectomy procedures. The market for thrombectomy devices used in AV access thrombectomy procedures is mature relative to the market for thrombectomy devices used in arterial and venous thrombectomy procedures.
Pulmonary embolism is a condition that affects over 600,000 individuals each year in the U.S. and leads to mortality in almost a third of those afflicted. This condition is caused by the accumulation of dislodged bodies in the lungs. These usually originate from blood clots or thrombi from a deep vein in the leg. Inferior vena cava filters (IVCFs) prevent pulmonary embolism by intercepting a thrombus before it can enter the circulatory system of the lungs.
The market for thrombectomy devices used in AV access thrombectomy procedures is mature relative to the market for thrombectomy devices used in arterial and venous thrombectomy procedures. The thrombectomy devices utilized in arterial and venous thrombectomy procedures are more sophisticated than the thrombectomy devices utilized in AV access thrombectomy procedures and therefore command a higher ASP.
Although anticoagulation therapy remains the first-line treatment for pulmonary embolism, IVCF unit sales are expected to increase over the forecast period. IVCFs can be classified as permanent or retrievable.